CAMRF (Camurus AB) ROC (Joel Greenblatt) %: 144.36% (As of Mar. 2026)


CAMRF Camurus AB CAMRF
83 GF Score
Price $54.00
GF Value $69.05
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB ROC (Joel Greenblatt) %?

Camurus AB CAMRF -3.57% 83 ROC (Joel Greenblatt) % is 144.36% as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $69.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,325 Biotechnology companies, Camurus AB ranks better than 96.23% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Camurus AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 144.36%.

The historical rank and industry rank for Camurus AB's ROC (Joel Greenblatt) % or its related term are showing as below:

CAMRF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2759.9   Med: -382.71   Max: 691.47
Current: 184.02

During the past 13 years, Camurus AB's highest ROC (Joel Greenblatt) % was 691.47%. The lowest was -2759.90%. And the median was -382.71%.

CAMRF's ROC (Joel Greenblatt) % is ranked better than
96.23% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs CAMRF: 184.02

Camurus AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Camurus AB  (OTCPK:CAMRF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Camurus AB ROC (Joel Greenblatt) % Related Terms


Camurus AB ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Camurus AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB ROC (Joel Greenblatt) % Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -192.98 86.10 695.72 370.67 269.58

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 311.16 298.66 226.16 103.71 144.36

CAMRF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Camurus AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Camurus AB's ROC (Joel Greenblatt) % falls into.


CAMRF
83GF Score
Camurus AB CAMRF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(46.223 + 12.011 + 4.183) - (13.544 + 0 + 23.799)
=25.074

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48.709 + 12.579 + 0) - (9.205 + 0 + 31.305)
=20.778

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Camurus AB for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=79.564/( ( (30.003 + max(25.074, 0)) + (34.374 + max(20.778, 0)) )/ 2 )
=79.564/( ( 55.077 + 55.152 )/ 2 )
=79.564/55.1145
=144.36 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 144.36% mean?
Camurus AB (CAMRF) has a ROC (Joel Greenblatt) % of 144.36% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #50 out of 1325 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Camurus AB's ROC (Joel Greenblatt) % too high?
Camurus AB's current ROC (Joel Greenblatt) % is 144.36%. Based on the distribution chart, Camurus AB ranks #50 out of 1325 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #50 out of 1325 companies for ROC (Joel Greenblatt) %. This places Camurus AB in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Camurus AB and its competitors. Camurus AB's current ROC (Joel Greenblatt) % is 144.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $69.05, compared to a current price of $54.00 — trading 21.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 144.36%. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current ROC (Joel Greenblatt) % is 144.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 21.8% below its estimated GF Value™ of $69.05. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for CAMRF:

  • ROC (Joel Greenblatt) %: 144.36%
  • GF Value™: $69.05 vs. price of $54.00 (21.8% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score

Get the complete analysis for CAMRF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$69.05
GF Value